Immunome Chief Scientific Officer Sells 9,438 Shares in Open-Market Transaction

Immunome’s Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock in an open-market transaction on April 2, 2026, according to an SEC Form 4 filing.

Transaction details

• Shares sold (direct): 9,438
• Transaction value: $204,238.32
• Post-transaction shares (direct): 22,000
• Post-transaction shares (indirect): 3,000
• Post-transaction value (direct ownership): $480,480

The transaction value was based on the SEC Form 4 reported price of $21.64 per share. The post-transaction value was based on the April 2, 2026 market close price of $21.84.

The filing also notes that 6,291 shares gifted on March 30, 2026 are excluded from the share counts, transaction values, and post-transaction balances referenced above.

Ownership impact

The sale reduced Higgins’s direct holdings by 30.02%, from 31,438 shares to 22,000 shares.

Higgins’s indirect holdings attributed to his children’s custodial accounts were not affected by this transaction and remain at 3,000 shares.

Timing and trading context

The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which the filing context indicates supports the view that the transaction was routine liquidity management rather than discretionary market timing.

In the available EDGAR filing history, one prior open-market sale was identified: 3,524 shares sold on August 15, 2024. The April 2, 2026 sale of 9,438 shares is approximately 2.7 times larger than that earlier transaction.

Company snapshot

• Price (market close 2026-04-02): $21.84
• Market capitalization: $2.40 billion
• Revenue (TTM): $6.94 million
• 1-year price change: 250.00%

What Immunome does

Immunome is a clinical-stage biotechnology company focused on antibody therapeutics for oncology and infectious diseases. Its lead programs include IMM-ONC-01 for cancer and IMM-BCP-01 for SARS-CoV-2. The company’s research-driven model aims to discover and advance proprietary antibody-based therapies for unmet needs.

Investor takeaways

Because the sale was tied to a Rule 10b5-1 plan set up in December 2025 for financial diversification, the transaction timing and price were established months in advance. After the sale, Higgins remained substantially invested, with a direct position valued at roughly $480,000 at the April 2 close.

For investors, the filing context emphasizes that company-specific milestones may be more informative than a pre-planned executive sale. The article highlights varegacestat’s Phase 3 RINGSIDE trial hitting its primary endpoint in December 2025, with an NDA submission planned for Q2 2026, alongside early data from IM-1021 and three IND submissions expected across 2026.